{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:41:29Z","timestamp":1791376889185,"version":"4.3.2"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) is an aggressive Grade IV brain tumor with a poor prognosis. It results from genetic mutations, epigenetic changes, and factors within the tumor microenvironment (TME). Traditional treatments like surgery, radiotherapy, and chemotherapy provide limited survival benefits due to the tumor's heterogeneity and resistance mechanisms. This review examines novel approaches for treating GBM, focusing on repurposing existing medications such as antipsychotics, antidepressants, and statins for their potential anti-GBM effects. Advances in molecular profiling, including next-generation sequencing, artificial intelligence (AI), and nanotechnology-based drug delivery, are transforming GBM diagnosis and treatment. The TME, particularly GBM stem cells and immune evasion, plays a key role in therapeutic resistance. Integrating multi-omics data and applying precision medicine show promise, especially in combination therapies and immunotherapies, to enhance clinical outcomes. Addressing challenges such as drug resistance, targeting GBM stem cells, and crossing the blood\u2013brain barrier is essential for improving treatment efficacy. While current treatments offer limited benefits, emerging strategies such as immunotherapies, precision medicine, and drug repurposing show significant potential. Technologies like liquid biopsies, AI-powered diagnostics, and nanotechnology could help overcome obstacles like the blood\u2013brain barrier and GBM stem cells. Ongoing research into combination therapies, targeted drug delivery, and personalized treatments is crucial. Collaborative efforts and robust clinical trials are necessary to translate these innovations into effective therapies, offering hope for improved survival and quality of life for GBM patients.<\/jats:p>","DOI":"10.1007\/s10238-025-01631-0","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T12:16:53Z","timestamp":1744546613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Emerging therapeutic strategies in glioblastsoma: drug repurposing, mechanisms of resistance, precision medicine, and technological innovations"],"prefix":"10.1007","volume":"25","author":[{"given":"Mohamed S.","family":"Anwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Abdel-Rasol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3622-1417","authenticated-orcid":false,"given":"Wael M.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,13]]},"reference":[{"issue":"8","key":"1631_CR1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"6","key":"1631_CR2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320.","journal-title":"Acta Neuropathol"},{"key":"1631_CR3","first-page":"574012","volume":"374","author":"C McKinnon","year":"2021","unstructured":"McKinnon C, Nandhabalan M, Murray SA, Plaha P. Glioblastoma: clinical presentation, diagnosis, and management. BMJ. 2021;374:574012.","journal-title":"BMJ"},{"key":"1631_CR4","doi-asserted-by":"crossref","first-page":"574012","DOI":"10.3389\/fonc.2020.574012","volume":"10","author":"B Oronsky","year":"2021","unstructured":"Oronsky B, Reid TR, Oronsky A, Sandhu N, Knox SJ. A review of newly diagnosed glioblastoma. Front Oncol. 2021;10:574012.","journal-title":"Front Oncol"},{"issue":"12","key":"1631_CR5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/ph17121687","volume":"17","author":"I Ntafoulis","year":"2024","unstructured":"Ntafoulis I, Koolen SL, van Tellingen O, den Hollander CW, Sabel-Goedknegt H, Dijkhuizen S, et al. A repurposed drug selection pipeline to identify CNS-penetrant drug candidates for glioblastoma. Pharmaceuticals. 2024;17(12):1687.","journal-title":"Pharmaceuticals"},{"issue":"7717","key":"1631_CR6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41586-018-0389-3","volume":"560","author":"JH Lee","year":"2018","unstructured":"Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature. 2018;560(7717):243\u20137.","journal-title":"Nature"},{"issue":"1","key":"1631_CR7","first-page":"48","volume":"60","author":"GS Stoyanov","year":"2018","unstructured":"Stoyanov GS, Dzhenkov DL. On the concepts and history of glioblastoma multiforme\u2014morphology. Genet Epigenet Folia Med (Plovdiv). 2018;60(1):48\u201366.","journal-title":"Genet Epigenet Folia Med (Plovdiv)"},{"issue":"2","key":"1631_CR8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462\u201377.","journal-title":"Cell"},{"issue":"9","key":"1631_CR9","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1007\/s12035-019-1561-y","volume":"56","author":"JR Kane","year":"2019","unstructured":"Kane JR. The role of brain vasculature in glioblastoma. Mol Neurobiol. 2019;56(9):6645\u201353.","journal-title":"Mol Neurobiol"},{"issue":"5","key":"1631_CR10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s43018-023-00556-5","volume":"4","author":"DC Watson","year":"2023","unstructured":"Watson DC, Bayik D, Storevik S, Moreino SS, Sprowls SA, Han J, et al. GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity. Nat Cancer. 2023;4(5):648\u201364.","journal-title":"Nat Cancer"},{"issue":"7961","key":"1631_CR11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41586-023-06036-1","volume":"617","author":"S Krishna","year":"2023","unstructured":"Krishna S, Choudhury A, Keough MB, Seo K, Ni L, Kakaizada S, et al. Glioblastoma remodelling of human neural circuits decreases survival. Nature. 2023;617(7961):599\u2013607.","journal-title":"Nature"},{"issue":"4","key":"1631_CR12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/0008-5472.CAN-13-1072","volume":"74","author":"Y Huang","year":"2014","unstructured":"Huang Y, Hoffman C, Rajappa P, Kim JH, Hu W, Huse J, et al. Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. Cancer Res. 2014;74(4):1011\u201321.","journal-title":"Cancer Res"},{"issue":"2","key":"1631_CR13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/ijms19020436","volume":"19","author":"S Roesch","year":"2018","unstructured":"Roesch S, Rapp C, Dettling S, Herold-Mende C. When immune cells turn bad\u2014tumor-associated microglia\/macrophages in glioma. Int J Mol Sci. 2018;19(2):436.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1631_CR14","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.3390\/cells10123529","volume":"10","author":"A Hern\u00e1ndez","year":"2021","unstructured":"Hern\u00e1ndez A, Dom\u00e8nech M, Mu\u00f1oz-M\u00e1rmol AM, Carrato C, Balana C. Glioblastoma: relationship between metabolism and immunosuppressive microenvironment. Cells. 2021;10(12):3529.","journal-title":"Cells"},{"issue":"20","key":"1631_CR15","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.4161\/cc.8.20.9701","volume":"8","author":"JM Heddleston","year":"2009","unstructured":"Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8(20):3274\u201385.","journal-title":"Cell Cycle"},{"key":"1631_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01887","author":"P Vaupel","year":"2017","unstructured":"Vaupel P, Multhoff G. Accomplices of the hypoxic tumor microenvironment compromising antitumor immunity: adenosine, lactate, acidosis, vascular endothelial growth factor, potassium ions, and phosphatidylserine. Front Immunol. 2017. https:\/\/doi.org\/10.3389\/fimmu.2017.01887.","journal-title":"Front Immunol"},{"issue":"3","key":"1631_CR17","first-page":"287","volume":"3","author":"L Oliver","year":"2020","unstructured":"Oliver L, Lalier L, Salaud C, Heymann D, Cartron PF, Vallette FM. Drug resistance in glioblastoma: are persisters the key to therapy? Cancer Drug Resist. 2020;3(3):287.","journal-title":"Cancer Drug Resist"},{"issue":"22","key":"1631_CR18","doi-asserted-by":"crossref","first-page":"12718","DOI":"10.1073\/pnas.2135113100","volume":"100","author":"YW Zhang","year":"2003","unstructured":"Zhang YW, Su Y, Volpert OV, Woude GF. Hepatocyte growth factor\/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA. 2003;100(22):12718\u201323.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1631_CR19","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1073\/pnas.1018154108","volume":"108","author":"JW Baish","year":"2011","unstructured":"Baish JW, Stylianopoulos T, Lanning RM, Kamoun WS, Fukumura D, Munn LL, et al. Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci USA. 2011;108(5):1799\u2013803.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"1631_CR20","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1016\/j.febslet.2008.06.033","volume":"582","author":"JL Lin","year":"2008","unstructured":"Lin JL, Wang MJ, Lee D, Liang CC, Lin S. Hypoxia-inducible factor-1\u03b1 regulates matrix metalloproteinase-1 activity in human bone marrow-derived mesenchymal stem cells. FEBS Lett. 2008;582(17):2615\u20139.","journal-title":"FEBS Lett"},{"key":"1631_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00265","author":"K Robinson","year":"2020","unstructured":"Robinson K, Tiriveedhi V. Perplexing role of P-glycoprotein in tumor microenvironment. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.00265.","journal-title":"Front Oncol"},{"issue":"10","key":"1631_CR22","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3390\/ijms19102879","volume":"19","author":"M Da Ros","year":"2018","unstructured":"Da Ros M, De Gregorio V, Iorio AL, Giunti L, Guidi M, De Martino M, et al. Glioblastoma chemoresistance: the double play by microenvironment and blood-brain barrier. Int J Mol Sci. 2018;19(10):2879.","journal-title":"Int J Mol Sci"},{"key":"1631_CR23","doi-asserted-by":"crossref","first-page":"979154","DOI":"10.3389\/fonc.2022.979154","volume":"12","author":"A Bogdanov","year":"2022","unstructured":"Bogdanov A, Bogdanov A, Chubenko V, Volkov N, Moiseenko F, Moiseyenko V. Tumor acidity: from hallmark of cancer to target of treatment. Front Oncol. 2022;12:979154.","journal-title":"Front Oncol"},{"issue":"10","key":"1631_CR24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/antiox13101201","volume":"13","author":"F Jamali","year":"2024","unstructured":"Jamali F, Lan K, Daniel P, Petrecca K, Sabri S, Abdulkarim B. Synergistic dual targeting of thioredoxin and glutathione systems irrespective of p53 in glioblastoma stem cells. Antioxidants. 2024;13(10):1201.","journal-title":"Antioxidants"},{"issue":"2","key":"1631_CR25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ane.12285","volume":"131","author":"JP Posti","year":"2015","unstructured":"Posti JP, Bori M, Kauko T, Sankinen M, Nordberg J, Rahi M, et al. Presenting symptoms of glioma in adults. Acta Neurol Scand. 2015;131(2):88\u201393.","journal-title":"Acta Neurol Scand"},{"issue":"19","key":"1631_CR26","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1212\/WNL.0000000000003911","volume":"88","author":"H Chen","year":"2017","unstructured":"Chen H, Judkins J, Thomas C, Wu M, Khoury L, Benjamin CG, et al. Mutant IDH1 and seizures in patients with glioma. Neurology. 2017;88(19):1805\u201313.","journal-title":"Neurology"},{"issue":"3","key":"1631_CR27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4103\/crst.crst_250_23","volume":"7","author":"G Bijalwan","year":"2024","unstructured":"Bijalwan G, Shrivastav AK, Mallik S, Dubey MK. Glioblastoma multiforme-a rare type of cancer: a narrative review. Cancer Res Stat Treat. 2024;7(3):340\u201351.","journal-title":"Cancer Res Stat Treat"},{"issue":"12","key":"1631_CR28","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","volume":"74","author":"F Sanger","year":"1977","unstructured":"Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74(12):5463\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"1631_CR29","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1101\/gr.3770505","volume":"15","author":"ML Metzker","year":"2005","unstructured":"Metzker ML. Emerging technologies in DNA sequencing. Genome Res. 2005;15(12):1767\u201376.","journal-title":"Genome Res"},{"issue":"23","key":"1631_CR30","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1002\/elps.200800456","volume":"29","author":"DG Hert","year":"2008","unstructured":"Hert DG, Fredlake CP, Barron AE. Advantages and limitations of next-generation sequencing technologies: a comparison of electrophoresis and non-electrophoresis methods. Electrophoresis. 2008;29(23):4618\u201326.","journal-title":"Electrophoresis"},{"issue":"6","key":"1631_CR31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/bies.200900181","volume":"32","author":"M Kircher","year":"2010","unstructured":"Kircher M, Kelso J. High-throughput DNA sequencing\u2013concepts and limitations. BioEssays. 2010;32(6):524\u201336.","journal-title":"BioEssays"},{"key":"1631_CR32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/2153-3539.103013","volume":"3","author":"RR Gullapalli","year":"2012","unstructured":"Gullapalli RR, Desai KV, Santana-Santos L, Kant JA, Becich MJ. Next generation sequencing in clinical medicine: challenges and lessons for pathology and biomedical informatics. J Pathol Inform. 2012;3:40.","journal-title":"J Pathol Inform"},{"issue":"1","key":"1631_CR33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrg2626","volume":"11","author":"ML Metzker","year":"2010","unstructured":"Metzker ML. Sequencing technologies\u2014the next generation. Nat Rev Genet. 2010;11(1):31\u201346.","journal-title":"Nat Rev Genet"},{"key":"1631_CR34","first-page":"449","volume":"5","author":"Y Wang","year":"2014","unstructured":"Wang Y, Yang Q, Wang Z. The evolution of nanopore sequencing. Front Genet. 2014;5:449.","journal-title":"Front Genet"},{"issue":"24","key":"1631_CR35","doi-asserted-by":"crossref","first-page":"13770","DOI":"10.1073\/pnas.93.24.13770","volume":"93","author":"JJ Kasianowicz","year":"1996","unstructured":"Kasianowicz JJ, Brandin E, Branton D, Deamer DW. Characterization of individual polynucleotide molecules using a membrane channel. Proc Natl Acad Sci USA. 1996;93(24):13770\u20133.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"1631_CR36","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nbt.1495","volume":"26","author":"D Branton","year":"2008","unstructured":"Branton D, Deamer DW, Marziali A, Bayley H, Benner SA, Butler T, et al. The potential and challenges of nanopore sequencing. Nat Biotechnol. 2008;26(10):1146\u201353.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1631_CR37","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nbt.4060","volume":"36","author":"M Jain","year":"2018","unstructured":"Jain M, Koren S, Miga KH, Quick J, Rand AC, Sasani TA, et al. Nanopore sequencing and assembly of a human genome with ultra-long reads. Nat Biotechnol. 2018;36(4):338\u201345.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"1631_CR38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00401-017-1743-5","volume":"134","author":"P Euskirchen","year":"2017","unstructured":"Euskirchen P, Bielle F, Labreche K, Kloosterman WP, Rosenberg S, Daniau M, et al. Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. Acta Neuropathol. 2017;134(5):691\u2013703.","journal-title":"Acta Neuropathol"},{"issue":"7216","key":"1631_CR39","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Cancer Genome Atlas Research N","year":"2008","unstructured":"Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061\u20138.","journal-title":"Nature"},{"issue":"8","key":"1631_CR40","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765\u201373.","journal-title":"N Engl J Med"},{"issue":"12","key":"1631_CR41","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/cancers11122025","volume":"11","author":"L Pang","year":"2019","unstructured":"Pang L, Hu J, Li F, Yuan H, Yan M, Liao G, et al. Discovering rare genes contributing to cancer stemness and invasive potential by GBM single-cell transcriptional analysis. Cancers. 2019;11(12):2025.","journal-title":"Cancers"},{"issue":"3","key":"1631_CR42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1073\/pnas.1320611111","volume":"112","author":"M Meyer","year":"2015","unstructured":"Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci USA. 2015;112(3):851\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"1631_CR43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.15252\/msb.20166969","volume":"12","author":"S Muller","year":"2016","unstructured":"Muller S, Liu SJ, Di Lullo E, Malatesta M, Pollen AA, Nowakowski TJ, et al. Single-cell sequencing maps gene expression to mutational phylogenies in PDGF- and EGF-driven gliomas. Mol Syst Biol. 2016;12(9):889.","journal-title":"Mol Syst Biol"},{"key":"1631_CR44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fonc.2018.00448","volume":"8","author":"M Romani","year":"2018","unstructured":"Romani M, Pistillo MP, Banelli B. Epigenetic targeting of glioblastoma. Front Oncol. 2018;8:448.","journal-title":"Front Oncol"},{"issue":"4","key":"1631_CR45","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2007.01.015","volume":"128","author":"B Li","year":"2007","unstructured":"Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell. 2007;128(4):707\u201319.","journal-title":"Cell"},{"issue":"5","key":"1631_CR46","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1586\/14789450.2.5.719","volume":"2","author":"L Marino-Ramirez","year":"2005","unstructured":"Marino-Ramirez L, Kann MG, Shoemaker BA, Landsman D. Histone structure and nucleosome stability. Expert Rev Proteom. 2005;2(5):719\u201329.","journal-title":"Expert Rev Proteom"},{"issue":"5532","key":"1631_CR47","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","volume":"293","author":"T Jenuwein","year":"2001","unstructured":"Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074\u201380.","journal-title":"Science"},{"issue":"7384","key":"1631_CR48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226\u201331.","journal-title":"Nature"},{"issue":"3","key":"1631_CR49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","volume":"21","author":"AJ Bannister","year":"2011","unstructured":"Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381\u201395.","journal-title":"Cell Res"},{"issue":"3","key":"1631_CR50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tcb.2023.07.011","volume":"34","author":"SI Sekine","year":"2024","unstructured":"Sekine SI, Ehara H, Kujirai T, Kurumizaka H. Structural perspectives on transcription in chromatin. Trends Cell Biol. 2024;34(3):211\u201324.","journal-title":"Trends Cell Biol"},{"key":"1631_CR51","doi-asserted-by":"crossref","first-page":"1481426","DOI":"10.3389\/fonc.2024.1481426","volume":"14","author":"RF Yekta","year":"2024","unstructured":"Yekta RF, Farahani M, Koushki M, Amiri-Dashatan N. Deciphering the potential role of post-translational modifications of histones in gastrointestinal cancers: a proteomics-based review with therapeutic challenges and opportunities. Front Oncol. 2024;14:1481426.","journal-title":"Front Oncol"},{"issue":"6","key":"1631_CR52","doi-asserted-by":"crossref","first-page":"9123","DOI":"10.18632\/oncotarget.13265","volume":"8","author":"SA Choi","year":"2017","unstructured":"Choi SA, Kwak PA, Park CK, Wang KC, Phi JH, Lee JY, et al. A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma. Oncotarget. 2017;8(6):9123\u201333.","journal-title":"Oncotarget"},{"issue":"5","key":"1631_CR53","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2353\/ajpath.2007.070011","volume":"170","author":"H Ohgaki","year":"2007","unstructured":"Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170(5):1445\u201353.","journal-title":"Am J Pathol"},{"issue":"1","key":"1631_CR54","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41467-019-09853-z","volume":"10","author":"A Dirkse","year":"2019","unstructured":"Dirkse A, Golebiewska A, Buder T, Nazarov PV, Muller A, Poovathingal S, et al. Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat Commun. 2019;10(1):1787.","journal-title":"Nat Commun"},{"issue":"23","key":"1631_CR55","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg DM, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. JAMA. 2017;318(23):2306\u201316.","journal-title":"JAMA"},{"issue":"12","key":"1631_CR56","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","volume":"37","author":"Z An","year":"2018","unstructured":"An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37(12):1561\u201375.","journal-title":"Oncogene"},{"issue":"29","key":"1631_CR57","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","volume":"38","author":"IK Mellinghoff","year":"2020","unstructured":"Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, et al. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020;38(29):3398\u2013406.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1631_CR58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385\u2013403.","journal-title":"Nat Rev Drug Discov"},{"key":"1631_CR59","doi-asserted-by":"crossref","first-page":"672508","DOI":"10.3389\/fonc.2021.672508","volume":"11","author":"SC Frederico","year":"2021","unstructured":"Frederico SC, Hancock JC, Brettschneider EES, Ratnam NM, Gilbert MR, Terabe M. Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma. Front Oncol. 2021;11:672508.","journal-title":"Front Oncol"},{"issue":"1","key":"1631_CR60","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41016-021-00269-7","volume":"8","author":"T Zhao","year":"2022","unstructured":"Zhao T, Li C, Ge H, Lin Y, Kang D. Glioblastoma vaccine tumor therapy research progress. Chin Neurosurg J. 2022;8(1):2.","journal-title":"Chin Neurosurg J"},{"issue":"3","key":"1631_CR61","doi-asserted-by":"crossref","first-page":"100748","DOI":"10.1016\/j.tranon.2020.100748","volume":"13","author":"W Wu","year":"2020","unstructured":"Wu W, Wu Y, Mayer K, von Rosenstiel C, Schecker J, Baur S, et al. Lipid peroxidation plays an important role in chemotherapeutic effects of temozolomide and the development of therapy resistance in human glioblastoma. Transl Oncol. 2020;13(3):100748.","journal-title":"Transl Oncol"},{"issue":"1","key":"1631_CR62","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41598-020-59146-5","volume":"10","author":"S Sheykhzadeh","year":"2020","unstructured":"Sheykhzadeh S, Luo M, Peng B, White J, Abdalla Y, Tang T, et al. Transferrin-targeted porous silicon nanoparticles reduce glioblastoma cell migration across tight extracellular space. Sci Rep. 2020;10(1):2320.","journal-title":"Sci Rep"},{"key":"1631_CR63","doi-asserted-by":"crossref","first-page":"e64090","DOI":"10.7554\/eLife.64090","volume":"10","author":"P Guilhamon","year":"2021","unstructured":"Guilhamon P, Chesnelong C, Kushida MM, Nikolic A, Singhal D, MacLeod G, et al. Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival. Elife. 2021;10:e64090.","journal-title":"Elife"},{"key":"1631_CR64","doi-asserted-by":"crossref","first-page":"106318","DOI":"10.1016\/j.phrs.2022.106318","volume":"182","author":"L Koh","year":"2022","unstructured":"Koh L, Novera W, Lim SW, Chong YK, Pang QY, Low D, et al. Integrative multi-omics approach to targeted therapy for glioblastoma. Pharmacol Res. 2022;182:106318.","journal-title":"Pharmacol Res"},{"issue":"2","key":"1631_CR65","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11060-015-1930-y","volume":"125","author":"D Cachia","year":"2015","unstructured":"Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, et al. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. J Neurooncol. 2015;125(2):401\u201310.","journal-title":"J Neurooncol"},{"issue":"10","key":"1631_CR66","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"issue":"4","key":"1631_CR67","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/neuonc\/noq193","volume":"13","author":"G Prasad","year":"2011","unstructured":"Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, et al. Inhibition of PI3K\/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011;13(4):384\u201392.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1631_CR68","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/s41467-018-04315-4","volume":"9","author":"FC Lam","year":"2018","unstructured":"Lam FC, Morton SW, Wyckoff J, Vu Han TL, Hwang MK, Maffa A, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 2018;9(1):1991.","journal-title":"Nat Commun"},{"issue":"3","key":"1631_CR69","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/cam4.614","volume":"5","author":"Y Nitta","year":"2016","unstructured":"Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y, Nagane M. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. Cancer Med. 2016;5(3):486\u201399.","journal-title":"Cancer Med"},{"issue":"26","key":"1631_CR70","doi-asserted-by":"crossref","first-page":"42495","DOI":"10.18632\/oncotarget.17205","volume":"8","author":"YJ Liu","year":"2017","unstructured":"Liu YJ, Ma YC, Zhang WJ, Yang ZZ, Liang DS, Wu ZF, et al. Combination therapy with micellarized cyclopamine and temozolomide attenuates glioblastoma growth through Gli1 down-regulation. Oncotarget. 2017;8(26):42495\u2013509.","journal-title":"Oncotarget"},{"issue":"7325","key":"1631_CR71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nature09624","volume":"468","author":"R Wang","year":"2010","unstructured":"Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468(7325):829\u201333.","journal-title":"Nature"},{"issue":"52","key":"1631_CR72","doi-asserted-by":"crossref","first-page":"89595","DOI":"10.18632\/oncotarget.19875","volume":"8","author":"AL Iorio","year":"2017","unstructured":"Iorio AL, da Ros M, Genitori L, Lucchesi M, Colelli F, Signorino G, et al. Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma. Oncotarget. 2017;8(52):89595\u2013606.","journal-title":"Oncotarget"},{"issue":"2","key":"1631_CR73","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","volume":"86","author":"J Zeng","year":"2013","unstructured":"Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1631_CR74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11060-015-1720-6","volume":"122","author":"B Raychaudhuri","year":"2015","unstructured":"Raychaudhuri B, Rayman P, Huang P, Grabowski M, Hambardzumyan D, Finke JH, et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol. 2015;122(2):293\u2013301.","journal-title":"J Neurooncol"},{"issue":"5897","key":"1631_CR75","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807\u201312.","journal-title":"Science"},{"key":"1631_CR76","first-page":"1213149","volume":"13","author":"X Guo","year":"2023","unstructured":"Guo X, Gu L, Li Y, Zheng Z, Chen W, Wang Y, et al. Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumors. Front Oncol. 2023;13:1213149.","journal-title":"Front Oncol"},{"issue":"5","key":"1631_CR77","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","volume":"6","author":"M Butler","year":"2020","unstructured":"Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, et al. MGMT status as a clinical biomarker in glioblastoma. Trends Cancer. 2020;6(5):380\u201391.","journal-title":"Trends Cancer"},{"issue":"9","key":"1631_CR78","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/cancers10090297","volume":"10","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Dube C, Gibert M, Cruickshanks N, Wang B, Coughlan M, et al. The p53 pathway in glioblastoma. Cancers. 2018;10(9):297.","journal-title":"Cancers"},{"issue":"1","key":"1631_CR79","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12672-023-00760-w","volume":"14","author":"F Tang","year":"2023","unstructured":"Tang F, Chen X, Liu JS, Liu ZY, Yang JZ, Wang ZF, et al. TERT mutations-associated alterations in clinical characteristics, immune environment, and therapy response in glioblastomas. Discover Oncol. 2023;14(1):148.","journal-title":"Discover Oncol"},{"issue":"Suppl 3","key":"1631_CR80","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/neuonc\/noad147.077","volume":"25","author":"SA Shboul","year":"2023","unstructured":"Shboul SA, Boyle S, Singh A, Saleh T, AlRjoub M, Al Karsaneh OA, et al. FISH-based investigation of CDKN2A and IFNA14 in glioblastoma. Neuro Oncol. 2023;25(Suppl 3):18.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1631_CR81","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s40478-024-01875-z","volume":"12","author":"M Chang","year":"2024","unstructured":"Chang M, Sherief M, Ioannou M, Chinnasamy V, Chen L, Frost M, et al. NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. Acta Neuropathol Commun. 2024;12(1):172.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"1631_CR82","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/1756-0500-3-293","volume":"3","author":"C Hagemann","year":"2010","unstructured":"Hagemann C, Anacker J, Haas S, Riesner D, Sch\u00f6mig B, Ernestus RI, et al. Comparative expression pattern of matrix-metalloproteinases in human glioblastoma cell lines and primary cultures. BMC Res Notes. 2010;3(1):293.","journal-title":"BMC Res Notes"},{"issue":"2","key":"1631_CR83","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12094-013-1059-4","volume":"16","author":"OF Olmez","year":"2014","unstructured":"Olmez OF, Cubukcu E, Evrensel T, Kurt M, Avci N, Tolunay S, et al. The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme. Clin Transl Oncol. 2014;16(2):173\u20137.","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"1631_CR84","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.7150\/jca.73365","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Mao X, Ye L, Cheng H, Dai X. The role of the S100 protein family in glioma. J Cancer. 2022;13(10):3022\u201330.","journal-title":"J Cancer"},{"issue":"14","key":"1631_CR85","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.3390\/ijms25147974","volume":"25","author":"AA Seyhan","year":"2024","unstructured":"Seyhan AA. Circulating liquid biopsy biomarkers in glioblastoma: advances and challenges. Int J Mol Sci. 2024;25(14):7974.","journal-title":"Int J Mol Sci"},{"key":"1631_CR86","doi-asserted-by":"crossref","first-page":"1303335","DOI":"10.3389\/fonc.2024.1303335","volume":"14","author":"X Wang","year":"2024","unstructured":"Wang X, Wang L, Lin H, Zhu Y, Huang D, Lai M, et al. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Front Oncol. 2024;14:1303335.","journal-title":"Front Oncol"},{"issue":"10","key":"1631_CR87","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/onco.13858","volume":"26","author":"L Gatto","year":"2021","unstructured":"Gatto L, Franceschi E, Di Nunno V, Tosoni A, Lodi R, Brandes AA. Liquid biopsy in glioblastoma management: from current research to future perspectives. Oncologist. 2021;26(10):865\u201378.","journal-title":"Oncologist"},{"issue":"3","key":"1631_CR88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41416-019-0603-6","volume":"122","author":"J M\u00fcller Bark","year":"2020","unstructured":"M\u00fcller Bark J, Kulasinghe A, Chua B, Day BW, Punyadeera C. Circulating biomarkers in patients with glioblastoma. Br J Cancer. 2020;122(3):295\u2013305.","journal-title":"Br J Cancer"},{"issue":"4","key":"1631_CR89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2022.13253","volume":"23","author":"I Bryukhovetskiy","year":"2022","unstructured":"Bryukhovetskiy I. Cell-based immunotherapy of glioblastoma multiforme. Oncol Lett. 2022;23(4):1\u201314.","journal-title":"Oncol Lett"},{"issue":"10","key":"1631_CR90","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41588-021-00926-8","volume":"53","author":"KC Johnson","year":"2021","unstructured":"Johnson KC, Anderson KJ, Courtois ET, Gujar AD, Barthel FP, Varn FS, et al. Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response. Nat Genet. 2021;53(10):1456\u201368.","journal-title":"Nat Genet"},{"issue":"4","key":"1631_CR91","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 2019;178(4):835-849.e21.","journal-title":"Cell"},{"issue":"6","key":"1631_CR92","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","volume":"40","author":"VM Ravi","year":"2022","unstructured":"Ravi VM, Will P, Kueckelhaus J, Sun N, Joseph K, Sali\u00e9 H, et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell. 2022;40(6):639-655.e13.","journal-title":"Cancer Cell"},{"issue":"12","key":"1631_CR93","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","volume":"3","author":"L Wang","year":"2022","unstructured":"Wang L, Jung J, Babikir H, Shamardani K, Jain S, Feng X, et al. A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. Nat Cancer. 2022;3(12):1534\u201352.","journal-title":"Nat Cancer"},{"key":"1631_CR94","first-page":"2024","volume":"7","author":"S Deacon","year":"2024","unstructured":"Deacon S, Cahyani I, Holmes N, Fox G, Munro R, Wibowo S, Murray T, Mason H, Housley M, Martin D, Sharif A. ROBIN: a unified nanopore-based sequencing assay integrating real-time, intraoperative methylome classification and next-day comprehensive molecular brain tumour profiling for ultra-rapid tumour diagnostics. medRxiv. 2024;7:2024\u2013109.","journal-title":"medRxiv"},{"issue":"9","key":"1631_CR95","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41591-019-0539-7","volume":"25","author":"PC Chen","year":"2019","unstructured":"Chen PC, Gadepalli K, MacDonald R, Liu Y, Kadowaki S, Nagpal K, et al. An augmented reality microscope with real-time artificial intelligence integration for cancer diagnosis. Nat Med. 2019;25(9):1453\u20137. https:\/\/doi.org\/10.1038\/s41591-019-0539-7.","journal-title":"Nat Med"},{"key":"1631_CR96","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"DS Wishart","year":"2006","unstructured":"Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34:D668\u201372. https:\/\/doi.org\/10.1093\/nar\/gkj067.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"1631_CR97","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.drudis.2017.08.010","volume":"22","author":"L Zhang","year":"2017","unstructured":"Zhang L, Tan J, Han D, Zhu H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug Discov Today. 2017;22(11):1680\u20135.","journal-title":"Drug Discov Today"},{"issue":"Suppl 11","key":"1631_CR98","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12859-017-1798-2","volume":"18","author":"JD Young","year":"2017","unstructured":"Young JD, Cai C, Lu X. Unsupervised deep learning reveals prognostically relevant subtypes of glioblastoma. BMC Bioinform. 2017;18(Suppl 11):381.","journal-title":"BMC Bioinform"},{"key":"1631_CR99","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1146\/annurev-med-051019-102940","volume":"72","author":"E Ricciotti","year":"2021","unstructured":"Ricciotti E, FitzGerald GA. Aspirin in the prevention of cardiovascular disease and cancer. Annu Rev Med. 2021;72:473\u201395.","journal-title":"Annu Rev Med"},{"issue":"21","key":"1631_CR100","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565\u201371.","journal-title":"N Engl J Med"},{"key":"1631_CR101","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","volume":"130","author":"FR Weth","year":"2024","unstructured":"Weth FR, Hoggarth GB, Weth AF, Paterson E, White MPJ, Tan ST, et al. Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. Br J Cancer. 2024;130:703\u201315.","journal-title":"Br J Cancer"},{"issue":"7","key":"1631_CR102","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.18632\/oncotarget.3243","volume":"6","author":"KH Liu","year":"2015","unstructured":"Liu KH, Yang ST, Lin YK, Lin JW, Lee YH, Wang JY, et al. Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis. Oncotarget. 2015;6(7):5088\u2013100.","journal-title":"Oncotarget"},{"issue":"4","key":"1631_CR103","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccr.2011.03.004","volume":"19","author":"OA Guryanova","year":"2011","unstructured":"Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 2011;19(4):498\u2013511.","journal-title":"Cancer Cell"},{"issue":"1","key":"1631_CR104","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00761-9","volume":"13","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zhao S, Fan Z, Li Z, Zhu Y, Shen T, et al. Metformin attenuates plaque-associated tau pathology and reduces amyloid-\u03b2 burden in APP\/PS1 mice. Alzheimers Res Ther. 2021;13(1):40.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1631_CR105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pbb.2012.07.015","volume":"103","author":"A Kumar","year":"2012","unstructured":"Kumar A, Prakash A, Pahwa D, Mishra J. Montelukast potentiates the protective effect of rofecoxib against kainic acid-induced cognitive dysfunction in rats. Pharmacol Biochem Behav. 2012;103(1):43\u201352.","journal-title":"Pharmacol Biochem Behav"},{"issue":"7","key":"1631_CR106","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/mds.28038","volume":"35","author":"E Bayram","year":"2020","unstructured":"Bayram E, Marras C, Standaert DG, Kluger BM, Bordelon YM, Shprecher DR, et al. Progressive supranuclear palsy and statin use. Mov Disord. 2020;35(7):1253\u20137.","journal-title":"Mov Disord"},{"issue":"1","key":"1631_CR107","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease. JAMA. 2016;316(1):40.","journal-title":"JAMA"},{"issue":"11","key":"1631_CR108","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","volume":"11","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509\u201323.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"1631_CR109","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1186\/s12967-023-04695-2","volume":"21","author":"S Sandouka","year":"2023","unstructured":"Sandouka S, Singh PK, Saadi A, Taiwo RO, Sheeni Y, Zhang T, et al. Repurposing dimethyl fumarate as an antiepileptogenic and disease-modifying treatment for drug-resistant epilepsy. J Transl Med. 2023;21(1):796.","journal-title":"J Transl Med"},{"issue":"2","key":"1631_CR110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1734-1140(12)70769-7","volume":"64","author":"MF El-Azab","year":"2012","unstructured":"El-Azab MF, Moustafa YM. Influence of calcium channel blockers on anticonvulsant and antinociceptive activities of valproic acid in pentylenetetrazole-kindled mice. Pharmacol Rep. 2012;64(2):305\u201314.","journal-title":"Pharmacol Rep"},{"issue":"2","key":"1631_CR111","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.expneurol.2011.01.017","volume":"229","author":"M Nizzardo","year":"2011","unstructured":"Nizzardo M, Nardini M, Ronchi D, Salani S, Donadoni C, Fortunato F, et al. Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms. Exp Neurol. 2011;229(2):214\u201325.","journal-title":"Exp Neurol"},{"issue":"5","key":"1631_CR112","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.18632\/oncotarget.1835","volume":"5","author":"J Bartek","year":"2014","unstructured":"Bartek J, Hodny Z. Dopamine signaling: target in glioblastoma. Oncotarget. 2014;5(5):1116\u20137.","journal-title":"Oncotarget"},{"issue":"1","key":"1631_CR113","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1535-7163.MCT-16-0169-T","volume":"16","author":"S Kang","year":"2017","unstructured":"Kang S, Hong J, Lee JM, Moon HE, Jeon B, Choi J, et al. Trifluoperazine, a well-known antipsychotic, inhibits glioblastoma invasion by binding to calmodulin and disinhibiting calcium release channel IP3R. Mol Cancer Ther. 2017;16(1):217\u201327.","journal-title":"Mol Cancer Ther"},{"issue":"1\u20132","key":"1631_CR114","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000444534","volume":"98","author":"MS Karbownik","year":"2016","unstructured":"Karbownik MS, Szemraj J, Wieteska \u0141, Antczak A, G\u00f3rski P, Kowalczyk E, et al. Antipsychotic drugs differentially affect mRNA expression of genes encoding the neuregulin 1-downstream ErbB4-PI3K pathway. Pharmacology. 2016;98(1\u20132):4\u201312.","journal-title":"Pharmacology"},{"issue":"1","key":"1631_CR115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11060-014-1688-7","volume":"122","author":"G Karpel-Massler","year":"2015","unstructured":"Karpel-Massler G, Kast RE, Westhoff MA, Dwucet A, Welscher N, Nonnenmacher L, et al. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide\u2019s antiproliferative effect. J Neurooncol. 2015;122(1):21\u201333.","journal-title":"J Neurooncol"},{"key":"1631_CR116","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-3-031-49963-0_23","volume-title":"Ischemic stroke therapeutics","author":"SR Belagaje","year":"2024","unstructured":"Belagaje SR, Brahmbhatt D, Abramoff BA. Selective serotonin reuptake inhibitors. In: Ischemic stroke therapeutics. Cham: Springer International Publishing; 2024. p. 313\u201321."},{"issue":"2","key":"1631_CR117","first-page":"391","volume":"30","author":"SC Higgins","year":"2010","unstructured":"Higgins SC, Pilkington GJ. The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma. Anticancer Res. 2010;30(2):391\u20137.","journal-title":"Anticancer Res"},{"issue":"6","key":"1631_CR118","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00280-017-3329-2","volume":"79","author":"AM Bielecka-Wajdman","year":"2017","unstructured":"Bielecka-Wajdman AM, Lesiak M, Ludyga T, Siero\u0144 A, Obuchowicz E. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme. Cancer Chemother Pharmacol. 2017;79(6):1249\u201356.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1631_CR119","doi-asserted-by":"crossref","first-page":"23372","DOI":"10.1038\/srep23372","volume":"6","author":"K Hayashi","year":"2016","unstructured":"Hayashi K, Michiue H, Yamada H, Takata K, Nakayama H, Wei FY, et al. Fluvoxamine, an antidepressant, inhibits human glioblastoma invasion by disrupting actin polymerization. Sci Rep. 2016;6(1):23372.","journal-title":"Sci Rep"},{"issue":"4","key":"1631_CR120","first-page":"1043","volume":"37","author":"S Tzadok","year":"2010","unstructured":"Tzadok S, Beery E, Israeli M, Uziel O, Lahav M, Fenig E, Gil-Ad I, Weizman A, Nordenberg J. In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells. Int J Oncol. 2010;37(4):1043\u201351.","journal-title":"Int J Oncol"},{"issue":"1","key":"1631_CR121","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-011-0725-z","volume":"107","author":"KA Van Nifterik","year":"2012","unstructured":"Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MVM, Sminia P, Stalpers LJA. Valproic acid sensitizes human glioma cells for temozolomide and \u03b3-radiation. J Neurooncol. 2012;107(1):61\u20137.","journal-title":"J Neurooncol"},{"issue":"3","key":"1631_CR122","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-016-2056-6","volume":"127","author":"CY Lee","year":"2016","unstructured":"Lee CY, Lai HY, Chiu A, Chan SH, Hsiao LP, Lee ST. The effects of antiepileptic drugs on the growth of glioblastoma cell lines. J Neurooncol. 2016;127(3):445\u201353.","journal-title":"J Neurooncol"},{"issue":"1","key":"1631_CR123","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/acschemneuro.6b00169","volume":"8","author":"R Pinheiro","year":"2017","unstructured":"Pinheiro R, Braga C, Santos G, Bronze MR, Perry MJ, Moreira R, et al. Targeting gliomas: can a new alkylating hybrid compound make a difference? ACS Chem Neurosci. 2017;8(1):50\u20139.","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"1631_CR124","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/stem.1956","volume":"33","author":"J Triscott","year":"2015","unstructured":"Triscott J, Rose Pambid M, Dunn SE. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram. Stem Cells. 2015;33(4):1042\u20136.","journal-title":"Stem Cells"},{"issue":"10","key":"1631_CR125","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.18632\/oncotarget.604","volume":"3","author":"J Triscott","year":"2012","unstructured":"Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, et al. Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide. Oncotarget. 2012;3(10):1112\u201323.","journal-title":"Oncotarget"},{"issue":"7684","key":"1631_CR126","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature25016","volume":"552","author":"Z Krott","year":"2017","unstructured":"Krott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017;552(7684):194\u20139.","journal-title":"Nature"},{"issue":"1","key":"1631_CR127","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2119\/molmed.2017.00011","volume":"23","author":"M De Witt","year":"2017","unstructured":"De Witt M, Gamble A, Hanson D, Markowitz D, Powell C, Al Dimassi S, et al. Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. Mol Med. 2017;23(1):50\u20136.","journal-title":"Mol Med"},{"issue":"27","key":"1631_CR128","doi-asserted-by":"crossref","first-page":"44255","DOI":"10.18632\/oncotarget.17464","volume":"8","author":"M Zheng","year":"2017","unstructured":"Zheng M, Sun W, Gao S, Luan S, Li D, Chen R, et al. Structure-based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1. Oncotarget. 2017;8(27):44255\u201365.","journal-title":"Oncotarget"},{"issue":"6","key":"1631_CR129","doi-asserted-by":"crossref","first-page":"e014961","DOI":"10.1136\/bmjopen-2016-014961","volume":"7","author":"RJ Molenaar","year":"2017","unstructured":"Molenaar RJ, Coelen RJ, Khurshed M, Roos E, Caan MW, van Linde ME, et al. Study protocol of a phase IB\/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. BMJ Open. 2017;7(6):e014961.","journal-title":"BMJ Open"},{"issue":"5","key":"1631_CR130","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3892\/ol.2012.843","volume":"4","author":"R Ferla","year":"2012","unstructured":"Ferla R, Haspinger E, Surmacz E. Metformin inhibits leptin-induced growth and migration of glioblastoma cells. Oncol Lett. 2012;4(5):1077\u201381.","journal-title":"Oncol Lett"},{"issue":"5","key":"1631_CR131","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/j.1476-5381.2011.01320.x","volume":"164","author":"R Kast","year":"2011","unstructured":"Kast R, Karpel-Massler G, Halatsch ME. Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzapine and metformin? Br J Pharmacol. 2011;164(5):1393\u20136.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1631_CR132","doi-asserted-by":"crossref","first-page":"e0123721","DOI":"10.1371\/journal.pone.0123721","volume":"10","author":"J Sesen","year":"2015","unstructured":"Sesen J, Dahan P, Scotland SJ, Saland E, Dang VT, Lemari\u00e9 A, et al. Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. PLoS ONE. 2015;10(4):e0123721.","journal-title":"PLoS ONE"},{"issue":"9","key":"1631_CR133","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1101\/gad.1540407","volume":"21","author":"YS Lee","year":"2007","unstructured":"Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007;21(9):1025\u201330.","journal-title":"Genes Dev"},{"issue":"22","key":"1631_CR134","doi-asserted-by":"crossref","first-page":"11252","DOI":"10.18632\/oncotarget.2617","volume":"5","author":"M Gritti","year":"2014","unstructured":"Gritti M, W\u00fcrth R, Angelini M, Barbieri F, Peretti M, Pizzi E, et al. Metformin repositioning as antitumoral agent: Selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. Oncotarget. 2014;5(22):11252\u201368.","journal-title":"Oncotarget"},{"issue":"6","key":"1631_CR135","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.canep.2014.09.010","volume":"38","author":"D Gaist","year":"2014","unstructured":"Gaist D, Hallas J, Friis S, Hansen S, S\u00f8rensen HT. Statin use and survival following glioblastoma multiforme. Cancer Epidemiol. 2014;38(6):722\u20137.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"1631_CR136","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-9966-30-74","volume":"30","author":"M Yanae","year":"2011","unstructured":"Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, et al. Statin-induced apoptosis via the suppression of ERK1\/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res. 2011;30(1):74.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01631-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01631-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01631-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:45:42Z","timestamp":1764917142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01631-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,13]]},"references-count":136,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1631"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01631-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,13]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"117"}}